HRP20250669T1 - Miv-818/lenvatinib kombinirana terapija za rak jetre - Google Patents

Miv-818/lenvatinib kombinirana terapija za rak jetre

Info

Publication number
HRP20250669T1
HRP20250669T1 HRP20250669TT HRP20250669T HRP20250669T1 HR P20250669 T1 HRP20250669 T1 HR P20250669T1 HR P20250669T T HRP20250669T T HR P20250669TT HR P20250669 T HRP20250669 T HR P20250669T HR P20250669 T1 HRP20250669 T1 HR P20250669T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
lenvatinib
miv
acceptable salt
combination
Prior art date
Application number
HRP20250669TT
Other languages
English (en)
Croatian (hr)
Inventor
Fredrik ÖBERG
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of HRP20250669T1 publication Critical patent/HRP20250669T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20250669TT 2020-04-15 2021-04-14 Miv-818/lenvatinib kombinirana terapija za rak jetre HRP20250669T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2050430 2020-04-15
PCT/SE2021/050338 WO2021211039A1 (en) 2020-04-15 2021-04-14 Miv-818/lenvatinib combination therapy for liver cancer
EP21787576.4A EP4135849B1 (en) 2020-04-15 2021-04-14 Miv-818/lenvatinib combination therapy for liver cancer

Publications (1)

Publication Number Publication Date
HRP20250669T1 true HRP20250669T1 (hr) 2025-08-01

Family

ID=78084457

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250669TT HRP20250669T1 (hr) 2020-04-15 2021-04-14 Miv-818/lenvatinib kombinirana terapija za rak jetre

Country Status (13)

Country Link
US (1) US20240024342A1 (https=)
EP (1) EP4135849B1 (https=)
JP (1) JP7709456B2 (https=)
KR (1) KR20230003522A (https=)
CN (1) CN115485029A (https=)
AU (1) AU2021255043B9 (https=)
CA (1) CA3174940A1 (https=)
ES (1) ES3027841T3 (https=)
HR (1) HRP20250669T1 (https=)
HU (1) HUE071473T2 (https=)
PL (1) PL4135849T3 (https=)
TW (1) TW202200140A (https=)
WO (1) WO2021211039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
TW202444368A (zh) * 2023-03-30 2024-11-16 瑞典商米迪維艾克提伯拉公司 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ729118A (en) * 2014-08-25 2022-02-25 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
CA3014769C (en) * 2016-03-02 2024-01-09 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
RU2019134940A (ru) * 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
US11098002B2 (en) * 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease

Also Published As

Publication number Publication date
EP4135849A1 (en) 2023-02-22
JP2023522325A (ja) 2023-05-30
US20240024342A1 (en) 2024-01-25
EP4135849B1 (en) 2025-03-19
EP4135849A4 (en) 2024-04-17
WO2021211039A1 (en) 2021-10-21
ES3027841T3 (en) 2025-06-17
AU2021255043B2 (en) 2025-06-05
KR20230003522A (ko) 2023-01-06
HUE071473T2 (hu) 2025-09-28
PL4135849T3 (pl) 2025-07-14
CN115485029A (zh) 2022-12-16
JP7709456B2 (ja) 2025-07-16
AU2021255043A1 (en) 2022-11-03
EP4135849C0 (en) 2025-03-19
AU2021255043B9 (en) 2025-07-10
CA3174940A1 (en) 2021-10-21
TW202200140A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
EP4635972A3 (en) Functionalized peptides as antiviral agents
MX2023001756A (es) Peptidos funcionalizados como agentes antivirales.
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
HRP20250480T1 (hr) Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
DE60319269D1 (de) Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen
HRP20250669T1 (hr) Miv-818/lenvatinib kombinirana terapija za rak jetre
HRP20251173T1 (hr) Triciklički parp1 inhibitori i njihove uporabe
JP2013507415A5 (https=)
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
IL273188B (en) Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
JP2024516363A5 (https=)
FI3972603T3 (fi) Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
HRP20241508T1 (hr) Kombinirana terapija sorafenibom ili regorafenibom i fosforamidatskim prolijekom troksacitabina
HRP20130071T1 (hr) Poboljšani testosteron u gelu i naäśin primjene
IL157466A (en) Combinations comprising a signal transduction inhibitor and an epothilone derivative, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for delay of progression or treatment of proliferative diseases
CA2560522A1 (en) Use of compounds for the prevention of drug-induced cell toxicity
UY39864A (es) Nuevos agentes antivirales derivados de espiropirrolidina
IL320024A (en) Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer
ME01335B (me) Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura
US20110028422A1 (en) Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
WO2004091633A8 (en) Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof